MX9700198A - Compuestos peptidos de proinsulina para detectar y tratar diabetes tipo 1. - Google Patents

Compuestos peptidos de proinsulina para detectar y tratar diabetes tipo 1.

Info

Publication number
MX9700198A
MX9700198A MX9700198A MX9700198A MX9700198A MX 9700198 A MX9700198 A MX 9700198A MX 9700198 A MX9700198 A MX 9700198A MX 9700198 A MX9700198 A MX 9700198A MX 9700198 A MX9700198 A MX 9700198A
Authority
MX
Mexico
Prior art keywords
proinsulin
diabetes
peptide compounds
proinsulin peptide
type
Prior art date
Application number
MX9700198A
Other languages
English (en)
Inventor
William F Hickey
Ann C Griffin
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955374&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9700198(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of MX9700198A publication Critical patent/MX9700198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)

Abstract

Se describen compuestos péptidos de proinsulina que modulan una respuesta inmunologica mediante las células T de sujetos diabéticos Tipo I. Los compuestos péptidos de proinsulina de la invencion se derivan de preferencia a partir de una region de proinsulina que abarca la union entre la cadena B y el péptido C de la proinsulina. También se describen composiciones farmacéuticas que comprenden los compuestos péptidos de proinsulina. Se puede usar una respuesta inmunologica a un compuesto péptido de proinsulina de la invencion, como un indicador de diabetes tipo I en un sujeto. De conformidad, la invencion proporciona ensayos de diagnostico para diabetes Tipo I usando los compuestos péptidos de proinsulina. También se describen métodos para la inhibicion del desarrollo o progreso de la diabetes Tipo I en un sujeto, mediante la administracion de un compuesto péptido de proinsulina.
MX9700198A 1994-07-08 1995-07-07 Compuestos peptidos de proinsulina para detectar y tratar diabetes tipo 1. MX9700198A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27222094A 1994-07-08 1994-07-08
US47270495A 1995-06-06 1995-06-06
PCT/US1995/008596 WO1996001846A1 (en) 1994-07-08 1995-07-07 Proinsulin peptide compounds for detecting and treating type i diabetes

Publications (1)

Publication Number Publication Date
MX9700198A true MX9700198A (es) 1997-04-30

Family

ID=26955374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700198A MX9700198A (es) 1994-07-08 1995-07-07 Compuestos peptidos de proinsulina para detectar y tratar diabetes tipo 1.

Country Status (12)

Country Link
US (1) US20030220229A1 (es)
EP (1) EP0788512B1 (es)
JP (1) JPH10505821A (es)
CN (1) CN1157621A (es)
AT (1) ATE178074T1 (es)
AU (1) AU3094795A (es)
CA (1) CA2194548A1 (es)
DE (1) DE69508605T2 (es)
DK (1) DK0788512T3 (es)
ES (1) ES2130629T3 (es)
MX (1) MX9700198A (es)
WO (1) WO1996001846A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815136B1 (en) 1995-02-20 2007-06-13 The Walter And Eliza Hall Institute Of Medical Research Immunoreactive and immunotherapeutic molecules which interact in subjects with insulin-dependent diabetes mellitus (iddm)
SE520392C2 (sv) 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
AUPO269996A0 (en) * 1996-10-01 1996-10-24 Walter And Eliza Hall Institute Of Medical Research, The A method of prophylaxis and treatment
US7509406B2 (en) * 2004-09-30 2009-03-24 Microsoft Corporation Managing terminal services accounts and sessions for online utilization of a hosted application
ES2331342B1 (es) * 2006-05-22 2010-10-13 Consejo Superior Investg.Cientificas Uso de la proinsulina para la elaboracion de una composicion farmaceutica neuroprotectora, composicion terapeutica que la contiene y sus aplicaciones.
CN103630692B (zh) * 2013-06-02 2015-05-06 马鞍山国声生物技术有限公司 快速检测尿液c肽的胶体金免疫层析试剂盒及其检测方法
JP6560200B2 (ja) * 2013-10-17 2019-08-14 ザ ジェネラル ホスピタル コーポレイション 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物
GB2559499A (en) * 2014-02-25 2018-08-08 Orban Tihamer Immunomodulatory therapy for type 1 diabetes mellitus autoimmunity
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5210872B2 (es) * 1973-07-14 1977-03-26
US4308181A (en) * 1980-12-08 1981-12-29 American Home Products Corporation Polypeptide compositions
US4652548A (en) * 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
NL9001083A (nl) * 1990-05-04 1991-12-02 Rijksuniversiteit Beta-cel antigeen.
ATE144326T1 (de) * 1990-08-17 1996-11-15 Univ Florida Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes

Also Published As

Publication number Publication date
US20030220229A1 (en) 2003-11-27
CA2194548A1 (en) 1996-01-25
EP0788512B1 (en) 1999-03-24
CN1157621A (zh) 1997-08-20
ES2130629T3 (es) 1999-07-01
DE69508605D1 (de) 1999-04-29
JPH10505821A (ja) 1998-06-09
DK0788512T3 (da) 1999-10-11
EP0788512A1 (en) 1997-08-13
DE69508605T2 (de) 1999-07-22
AU3094795A (en) 1996-02-09
ATE178074T1 (de) 1999-04-15
WO1996001846A1 (en) 1996-01-25

Similar Documents

Publication Publication Date Title
Lester et al. Human alpha-fetoprotein as a modulator of human lymphocyte transformation: correlation of biological potency with electrophoretic variants.
HK1041293B (zh) 細胞外新的rage粘合蛋白(en-rage)及其用途
ES8605644A1 (es) Procedimiento para la preparacion de un suero de control o calibrado
PT1075259E (pt) Novos analogos gordos para o tratamento de diabetes
TR200000740T2 (tr) Dişleri beyazlatmak için metod ve kompozisyonlar.
ES8707547A1 (es) Procedimiento para preparar un oligopeptidil-argininol u-homoargininol o derivado de estos
AU1929199A (en) Methods for the recovery and measurement of troponin complexes
ATE69239T1 (de) Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung.
ATE32728T1 (de) Modifizierte protease-inhibitoren, verfahren zu ihrer herstellung und daraus bereitete pharmazeutische mittel.
MX9700198A (es) Compuestos peptidos de proinsulina para detectar y tratar diabetes tipo 1.
DK93685A (da) Benzisoselenazolthioner, fremgangsmaade til fremstilling af disse forbindelser og farmaceutiske praeparater indeholdende disse forbindelser
EP1903058A3 (en) Extracellular novel rage binding protein (en-rage) and uses thereof
DK0749582T3 (da) Fremgangsmåde til diagnosticering af præeklampsi
IL128893A0 (en) Materials and methods relating to the diagnosis and treatment of pre-eclampsio and diabetes
SG54339A1 (en) Novel crystal form of anhydrous 7-(1alpha,salpha, 6alpha,]-6-amino-3-azabicyclo [3.1.0]hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl) (pls refer to file for full detail)
GR862201B (en) Polypeptides and antibodies characteristic of papillomavirus and their application to in vitro diagnosis the prevention and the fight against the infections by the papillomavirus
ATE13433T1 (de) Peptide als arzneimittel und einige peptide.
TR199800521T1 (xx) Se�imli beta3 adrenerjik agonistler.
DE59508137D1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
WO1996001846B1 (en) Proinsulin peptide compounds for detecting and treating type i diabetes
TR200101083T2 (tr) (7alfa,17alfa)-17-hidroksi- 7-metil-19-nor-17-pregn-5 (10)-en-20-in-3-on içeren yüksek saflıkta bileşim.
FI971427A (fi) Peptidit ja niitä sisältävät farmaseuttiset koostumukset
AU3088984A (en) Antibodies and compositions thereof for inhibiting dental induced by s. abitans
DK0972032T3 (da) Peptider til behandling af systemisk lupus erythematosus
DE69518246D1 (de) Aminosäuren konjugaten

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees